Gubra A/S

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

0.69%

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

205m

+2.82%

Net income

-45m

CFO

-49m

Profile

Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company was incorporated in 2008 and is based in Horsholm, Denmark.

URL

https://www.gubra.dk/

IPO date

Apr 04, 2023

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title in thousands, except ratios and share amounts	FY	FY	FY	FY	FY
Title in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT